apob

(redirected from apoB-100)
Also found in: Medical.

apob

[′ā‚päb]
(meteorology)
An observation of pressure, temperature, and relative humidity taken aloft by means of an aerometeorograph; a type of aircraft sounding.
Mentioned in ?
References in periodicals archive ?
reuteri organisms in capsule form for nine weeks, LDL cholesterol fell by nearly 12%, total cholesterol fell by 9%, non-HDL cholesterol fell by 11%, and apoB-100 fell by 8%, with a reduction in the LDL to HDL cholesterol ratio of 13%.
Mipomersen is a second-generation antisense drug currently in phase 3 development that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol.
Mipomersen is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol.
The therapy is intended to reduce the production of ApoB-100, a protein that carries certain forms of cholesterol and triglycerides in the blood.
We conclude that a redox active copper-rutin-complex is still able to initiate the LDL oxidation but may prevent copper from a reaction at the binding sites of apoB-100.
There was also no change in the plasma lathosterol, serum apoB-100 or lipids with chronic black tea ingestion.
The APOB gene is located on chromosome 2 and produces, via a unique mRNA editing process, two forms of apoB in circulating lipoproteins, apoB-48 and apoB-100 (3).
ApoB-100 is the carrier of LDL cholesterol, the "bad" lipid involved in heart disease.
ApoB-100 and ApoB/ApoA-1 ratio in children and adolescents from families with very early myocardial infarction.
Triglycerides of dietary origin enter the circulation as chylomicrons, the largest of lipoprotein particles (80-1000 nm) packaged together with the truncated form of apolipoprotein B, apoB-48, whereas fatty acids originating in the liver are secreted as VLDL (25-80 nm) with apoB-100.
presented the results of two studies designed to assess the impact of lowering apoB-100 on atherosclerosis at the 2008 Annual Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Conference in Atlanta, Georgia.